What happened
Matthew Gallagher founded Medvi, a telehealth company, using AI tools including ChatGPT, Claude, Grok for coding, Midjourney and Runway for marketing, and ElevenLabs for customer communication. Launched in September 2024 with $20,000, Medvi generated $401 million in 2025 from 250,000 customers, projecting $1.8 billion in 2026 with a minimal two-person team. The company sells GLP-1 drugs, with compounded semaglutide starting at $179 for the first month. The FDA issued a warning letter to Medvi on February 20, 2026, citing misbranding of compounded drugs and misleading claims about FDA approval.
Why it matters
AI tools enable founders to scale companies to significant valuations, automating development, marketing, and customer support, reducing operational overhead. This shifts unit economics for entrepreneurs, allowing rapid market entry and growth. However, the rapid, AI-driven scaling of services in highly regulated sectors like prescription drug sales introduces compliance risks for legal and procurement teams, as evidenced by Medvi's FDA warning letter regarding misbranding and misleading claims.
Subscribe for Weekly Updates
Stay ahead with our weekly AI and tech briefings, delivered every Tuesday.
